Cost-effectiveness analysis compares follitropin delta's outcomes in ART, suggesting potential savings.
Follitropin delta provides an effective alternative to follitropin alfa and beta with a potential cost-savings opportunity, excluding the delivery cost, due to higher OP and LB rates in the fresh cycle transfers.
No takes yet. Share an insight, caveat, or question.
Hamamah et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: